Compare SDRL & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SDRL | CPRX |
|---|---|---|
| Founded | 2005 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.9B |
| IPO Year | 2018 | 2006 |
| Metric | SDRL | CPRX |
|---|---|---|
| Price | $45.29 | $23.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $51.75 | $35.00 |
| AVG Volume (30 Days) | 727.1K | ★ 1.0M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.61 | 28.24 |
| EPS | N/A | ★ 1.68 |
| Revenue | ★ $1,437,000,000.00 | $119,072,803.00 |
| Revenue This Year | $4.57 | $9.20 |
| Revenue Next Year | $14.36 | $10.51 |
| P/E Ratio | ★ N/A | $14.42 |
| Revenue Growth | 3.75 | ★ 16.39 |
| 52 Week Low | $18.60 | $19.05 |
| 52 Week High | $46.20 | $26.56 |
| Indicator | SDRL | CPRX |
|---|---|---|
| Relative Strength Index (RSI) | 59.80 | 47.92 |
| Support Level | $41.63 | $23.27 |
| Resistance Level | N/A | $24.94 |
| Average True Range (ATR) | 1.66 | 0.65 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 80.76 | 39.14 |
Seadrill Ltd is an offshore drilling contractor company. The company is engaged in providing offshore drilling services to the oil and gas industry. The primary business of the company is the ownership and operation of drillships, semi-submersible rigs, and jack-up rigs for operations in shallow to ultra-deepwater areas in both benign and harsh environments. The geographical segments of the company are the United States, Brazil, Angola, Norway, Canada and others. The company derives maximum revenue from the United States.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.